Aspergillus fumigatus, lethal fungus spreading across US raises alarm — Florida, Texas, California & more states at risk

A deadly fungus that can rot human tissue from within is rapidly spreading across the United States, with experts sounding alarm over rising temperatures, widespread drug resistance, and the lack of national disease tracking. According to a report in The Daily Mail, the airborne fungus Aspergillus fumigatus is nearly impossible to avoid and poses an especially grave risk to individuals with weakened immune systems.
The fungus causes aspergillosis, a serious lung infection that can lead to organ failure and death, particularly in cancer, asthma, or HIV patients. As the news report notes, its spores are so small they are inhaled without notice. Once inside the lungs, the fungus can trigger chronic infections or even spread to the brain, heart, and kidneys in more invasive forms.
Despite its danger, aspergillosis is not a reportable disease in the US — meaning infections, hospitalizations, and fatalities are not systematically tracked, making outbreaks difficult to identify.
Citing health data, the news outlet reported that invasive aspergillosis hospitalisations in the US rose by around 3% annually between 2000 and 2013. By 2014, nearly 15,000 hospital stays were linked to the infection, costing an estimated $1.2 billion. Intensive care autopsies also revealed it ranks among the top four infections most likely to cause death.
Around 400,000 people are estimated to suffer from chronic pulmonary aspergillosis, the long-term form of the disease. Invasive cases, though less common, are far more fatal — with only 59% of organ transplant patients surviving a year after infection, and just 25% of stem cell transplant patients, according to studies cited by The Daily Mail.
The fungus thrives in warm, damp environments and can survive temperatures above 120°F in compost piles. According to The Daily Mail, the highest exposure levels are being recorded in Florida, Louisiana, Texas, Georgia, and California — states with hot, humid climates and extensive farming activity. Dense urban centers like New York, Houston, and Los Angeles are also vulnerable due to aging infrastructure and population density.
A University of Manchester study warned, the news report stated, that if fossil fuel use continues unchecked, Aspergillus fumigatus could expand by over 75% by 2100, putting millions more at risk across the southern US.
Perhaps most concerning is the rising drug resistance. Azole antifungal drugs — commonly used to treat human infections — are also widely applied in agriculture to protect crops. Experts cited by the news outlet said that this practice may be driving environmental resistance, with drug-resistant fungal spores jumping from soil to humans.
A study in Applied and Environmental Microbiology found azole-resistant strains of Aspergillus fumigatus in farm soils across at least seven US states. Some strains are resistant to multiple standard treatments, and the mixing of fungal types may be accelerating the resistance crisis.
The World Health Organization has named Aspergillus fumigatus a "critical priority" due to its high mortality rates and the increasing threat of untreatable infections. The news outlet reported that the WHO is urging global investment in new antifungal drugs, faster diagnostic tools, improved hospital protocols, and enhanced training for healthcare professionals. The organization is also calling on pharmaceutical firms to include children in clinical trials for fungal treatments.
Doctors are advising those with compromised immune systems to avoid gardening, soil, and moldy environments, wear protective masks in dusty areas, and ensure clean air circulation in hospitals and homes. US hospitals have begun strengthening mold inspections and antifungal protocols in response to the growing concern.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Time of India

an hour ago

• Time of India

Tripura CM mulls sex education in Class VIII-XII curriculum

Agartala: Tripura CM on Friday said the state govt is considering the introduction of sex education in the curriculum for students in Classes VIII to XII. Speaking at the legislative forum in the state assembly, Saha emphasised the importance of this initiative, stating, "We are considering incorporating sex education and HIV/AIDS awareness in the school curriculum in Class VIII-XII. Tired of too many ads? go ad free now This is not a matter of controversy, it is a necessity." He also encouraged community involvement, suggesting that MLAs could allocate funds to support HIV/AIDS patients. Saha highlighted the equal impact of HIV/AIDS on both boys and girls and stressed the importance of engaging youth in sports, cultural activities, and other creative pursuits to steer them away from drug addiction and reduce their vulnerability to HIV/AIDS. He said Tripura was the first state in India to introduce Red Ribbon Clubs in schools and plans to create youth ambassadors to lead campaigns against drug abuse. Expressing concern over the rising number of HIV/AIDS cases and injecting drug users, particularly among teenagers, Saha said an average of 120 new HIV infections are reported each month in the state, despite preventive efforts by the state AIDS Control Society. In response to a proposal by Congress legislator Sudip Roybarman, the chief minister supported the idea of adding a dedicated chapter on sex education and HIV/AIDS to the school curriculum to raise awareness among the most vulnerable age group. Additionally, he suggested that each MLA could allocate Rs 1 lakh per year from their area development fund for initiatives against drugs and HIV.

Indian Express

4 hours ago

• Indian Express

As US FDA approves HIV prevention drug Lenacapavir, expert says ‘India needs to take lead for its equitable, timely distribution

The United States Food and Drug Administration (FDA) on Wednesday approved Lenacapavir (LEN), the most promising HIV prevention medicine to be made so far, and according to Dr I S Gilada, president emeritus, AIDS Society of India, the real breakthrough would be when LEN becomes accessible, affordable and available to everyone in India and across the world. Lenacapavir is an antiretroviral medicine that is used for HIV prevention as a pre-exposure prophylaxis or PrEP. PrEP is a medication that can reduce the risk of HIV infection for individuals who are HIV-negative but are at risk of contracting the virus. The results of two key studies have shown that it helps prevent 99.9 per cent of all HIV transmission. 'LEN is an injectable PrEP that is to be taken twice yearly,' said Dr Glory Alexander, president of AIDS Society of India (ASI) and founder director of ASHA Foundation, Bengaluru. PrEP was first approved by the US FDA in 2012, but the Indian government's National AIDS Control Organisation is yet to roll it out. 'If we invest in HIV prevention, we not only protect people's health but also save expenses in providing lifelong HIV care, including lifelong antiretroviral therapy (ART). HIV prevention must remain at the centre-stage of our national AIDS response,' said Dr Gilada. 'Indian regulators should work with Indian generic manufacturing companies to ensure that 'made in India' generic LEN versions when available, are first rolled out in India,' Dr Gilada told The Indian Express. 'The scientific breakthrough translates into public health impact in terms of stopping the spread of HIV infection. The major impediment is the cost: LEN as PrEP to be sold as Yeztugo by Gilead is priced at US$ 28,218 per person per year. However, Gilead's wisdom by giving voluntary licenses to four Indian generic companies, gives hope that the medicine may cost less than US$ 100 – that is 0.3 per cent of the innovator's cost,' Dr Gilada explained. 'India needs to lead from the front for LEN's equitable and timely distribution at the required scale to prevent HIV transmission and help end AIDS,' said Dr Gilada, adding that only India can deliver LEN to all those in need worldwide, in terms of quality, quantity and speed. Though India meets 92 per cent of the global requirement for ART and the global community (WHO, UNAIDS, Global Fund, World Bank, etc) widely uses Indian generic pharma for their strategies like Treatment as Prevention (TasP), Test and Treat, Post-exposure Prophylaxis (PEP), PreP, etc, it is unfortunate that they are shy to acknowledge this, he said. Gilead had faced a lot of backlash from health advocates and communities last year over the astronomical pricing for LEN, pegged at over US$ 40,000 per person per year, which has now been slashed by 30 per cent. Earlier, Gilead's Hepatitis C treatment, which cost $84,000 in the US for a three-month course, was made available in India for less than $300. So the firm knew what was to be done this time, and granted voluntary licensing to six generic manufacturers, including four Indian: Dr Reddy's Laboratories, Emcure, Hetero Healthcare, and Viatris. 'All international antiretroviral therapy and prevention guidelines are conceptualised and implemented on the strength of India. Only India can meet the global demand for LEN at such low cost, just as it did for ART, at 0.3 per cent of the innovator's cost,' Dr Gilada said. Anuradha Mascarenhas is a journalist with The Indian Express and is based in Pune. A senior editor, Anuradha writes on health, research developments in the field of science and environment and takes keen interest in covering women's issues. With a career spanning over 25 years, Anuradha has also led teams and often coordinated the edition. ... Read More

Indian Express

10 hours ago

• Indian Express

US FDA approves HIV prevention drug: Why is this a breakthrough?

A twice-yearly injectable drug for the prevention of HIV infection has been approved by the United States' Food and Drug Administration. With better compliance expected — instead of daily pills on a shot every two months that people have to take at the moment — it is one of the most anticipated developments in the field of HIV prevention. The Lenacapavir injection — sold as Yeztugo by pharmaceutical giant Gilead — was approved based on the results of two Phase 3 trials that showed 99.9% of individuals remained HIV negative with the two shots taken annually. 'FDA approval … paves the way for WHO prequalification, which can accelerate national regulatory approvals … and procurement by donor agencies like the Global Fund… Lenacapavir's discreet, long-acting formulation may help overcome key barriers such as daily pill burden, frequent clinic visits and stigma associated with HIV prevention,' the World Health Organization (WHO) said. Lenacapavir is an anti-retroviral medication that can be used to treat as well as prevent HIV. As Sunlenca, it is used in combination with other antiretroviral drugs for the treatment of people who have been on pills for a very long time and are resistant to multiple drugs. As Yestugo, it is a pre-exposure prophylaxis (PrEP) to prevent the infection. The drug works by binding with the HIV capsid — a protein shell that protects the virus' genetic material. It then disrupts crucial steps needed for the virus to replicate and infect new cells. PrEP or pre-exposure prophylaxis is a drug or injectable meant to prevent HIV infection in people at a higher risk of contracting the disease. These medicines can reduce the risk of acquiring HIV infection through sexual activity by 99% and through injection drug use by 74%. At present, there are several types of PrEP available — pills such as Truvada or Descovy, Dapivirine vaginal ring and the injectable Cabotegravir that has to be taken every two months. It is important to be tested for HIV before taking PrEP. While these medicines are also used in the treatment of HIV, they are prescribed in combination with other antiretrovirals. Given alone to a patient with HIV, they might develop resistance to the drugs. PrEP is usually recommended for people living with an HIV positive partner, those who frequently change partners, those who have sex with people with unknown HIV status, those who work in the sex industry, and those who use injectable drugs. Medicines for post exposure prophylaxis are also available to be used as an emergency measure in cases such as inadvertent exposure in a hospital setting, after condom failure, or during sexual assault. While generic versions of the PrEP pills are approved in India — Cabotegravir injection is also available through a sub-licensing contract — they are not widely used. This is mainly owing to the cost of the medicines and the fact that they are not yet part of the country's national programme, which already provides life-long treatment to all who have been diagnosed with HIV. The new injectable will cost USD 28,218 annually, remaining out of reach for many. Even in the US, usage remains low. Only 36% of the 1.2 million people who would have benefited from the medicine were prescribed it. Anonna Dutt is a Principal Correspondent who writes primarily on health at the Indian Express. She reports on myriad topics ranging from the growing burden of non-communicable diseases such as diabetes and hypertension to the problems with pervasive infectious conditions. She reported on the government's management of the Covid-19 pandemic and closely followed the vaccination programme. Her stories have resulted in the city government investing in high-end tests for the poor and acknowledging errors in their official reports. Dutt also takes a keen interest in the country's space programme and has written on key missions like Chandrayaan 2 and 3, Aditya L1, and Gaganyaan. She was among the first batch of eleven media fellows with RBM Partnership to End Malaria. She was also selected to participate in the short-term programme on early childhood reporting at Columbia University's Dart Centre. Dutt has a Bachelor's Degree from the Symbiosis Institute of Media and Communication, Pune and a PG Diploma from the Asian College of Journalism, Chennai. She started her reporting career with the Hindustan Times. When not at work, she tries to appease the Duolingo owl with her French skills and sometimes takes to the dance floor. ... Read More